71556-74-6

Basic information

• Product Name: 3-ETHYL-3-(3-HYDROXYPHENYL)-1-METHYLAZEPAN-2-ONE
• Synonyms: 3-ETHYL-3-(3-HYDROXYPHENYL)-1-METHYLAZEPAN-2-ONE;3-ethylhexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one;3-Ethyl-3-(3-hydroxyphenyl)-1-methylazepan-2-one, tech
• CAS NO: 71556-74-6
• Molecular Formula: C₁₅H₂₁NO₂
• Molecular Weight: 247.33
• EINECS: 275-622-0
• Mol File: 71556-74-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 172 °C
• Boiling Point: 429.8 °C at 760 mmHg
• Flash Point: 213.7 °C
• Appearance: /
• Density: 1.073
• Vapor Pressure: 5.43E-08mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-ETHYL-3-(3-HYDROXYPHENYL)-1-METHYLAZEPAN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ETHYL-3-(3-HYDROXYPHENYL)-1-METHYLAZEPAN-2-ONE(71556-74-6)
• EPA Substance Registry System: 3-ETHYL-3-(3-HYDROXYPHENYL)-1-METHYLAZEPAN-2-ONE(71556-74-6)

Safety Data

• Statements: 20/21/22-36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 71556-74-6(Hazardous Substances Data)

Usage

Uses

3-Ethyl-3-(3-hydroxyphenyl)-1-methylazepan-2-one (cas# 71556-74-6) is an impurity of meptazinol, which is a mixed opioid agonist-antagonist. Analgesic (narcotic).

InChI:InChI=1/C15H21NO2/c1-3-15(12-7-6-8-13(17)11-12)9-4-5-10-16(2)14(15)18/h6-8,11,17H,3-5,9-10H2,1-2H3

Upstream product

• 71592-43-3 hexahydro-3-(3-methoxyphenyl)-1-methyl-2H-azepin-2-one 
• 71556-70-2 hexahydro-1-methyl-3-(3-oxocyclohexen-1-yl)<2H>azepin-2-one 
• 105-60-2 caprolactam 
• 2556-73-2 1-methyl-2-azepanone 
• 71556-72-4 3-Ethyl-hexahydro-3-(3-methoxyphenyl)-1-methyl-2H-azepin-2-one 
• 87887-09-0 3-(2-bromo-3-oxocyclohex-1-enyl)-3-ethylhexahydro-1-methylazepin-2-one 
• 87887-10-3 3-(2-chloro-3-oxocyclohex-1-enyl)-3-ethylhexahydro-1-methylazepin-2-one 
• 71592-44-4 hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one 
• 75-03-6 ethyl iodide 
• 71556-77-9 3-ethyl-hexahydro-1-methyl-3-(3-oxocyclohexen-1-yl)-2H-azepin-2-one 
• 766-51-8 2-Chloroanisole 

Downstream Products

• 1262385-30-7 C₂₅H₃₈N₂O₅ 
• 275806-98-9 2-[3-(3S-ethyl-1-methyl-2-oxo-azepan-3-yl)-phenoxy]-4-[1-methylamino-1-(3-methyl-3H-imidazol-4-yl)-ethyl]-benzonitrile 
• 275807-75-5 2-[3-(3-ethyl-1-methyl-2-oxoazepan-3-yl)phenoxy]-4-(1-trityl-1H-imidazol-4-ylmethyl)benzonitrile 
• 301296-47-9 2-[3-(3-Ethyl-1-methyl-2-oxo-azepan-3-yl)-phenoxy]-4-(3-methyl-3H-imidazole-4-carbonyl)-benzonitrile 
• 275806-12-7 2-[3-(3-ethyl-1-methyl-2-oxo-azepan-3-yl)-phenoxy]-4-[hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-benzonitrile 
• 54340-58-8 3-(3-ethyl-1-methyl-1H-hexahydroazepin-3-yl)phenol 

Relevant articles and documents

Method for preparing MPTF-E (meptazinol E)

The invention discloses a method for preparing MPTF-E (meptazinol E), and belongs to the technical field of chemical drug preparation. The method comprises the following steps: (1) chloroanisole reacts with N-methylcaprolactam, and a compound I is obtained; (2) the compound I reacts with iodoethane, and a compound II is obtained; (3) boron bromide reacts with the compound II, and a compound III is obtained; (4) the compound III reacts with bromobutane, and a compound IV is obtained; (5) the compound IV is dissolved in anhydrous THF (tetrahydrofuran), lithium aluminum hydride is added, reaction reflux is performed, reactants are cooled to the room temperature, H2O is slowly added to a reaction liquid, then MgSO4 is added for stirring, filtration, reduced-pressure distillation and purification are performed, and a compound V is obtained. The method has the following advantages that MPTF-E is synthesized for the first time, and qualified impurity E comparison products are provided for meptazinol; a reagent adopted is a common solvent and easy to obtain; safe solvents such as ethyl acetate, petroleum ether and the like are used for treatment and have low toxicity; the process is simple and easy to operate, little energy is consumed, the stability is high, and the purity is high.

Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents

A series of novel diaryl ether lactams have been identified as very potent dual inhibitors of protein farnesyltransferase (FTase) and protein geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of Ras. The structure of the complex formed between one of these compounds and FTase has been determined by X-ray crystallography. These compounds are the first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly lethal.

2-Bromo-3-methoxycyclohex-2-enone, a New Reagent for the α-Arylation of Lactams

We report efficient syntheses of 2-bromo and 2-chloro-3-methoxycyclohex-2-enone and their use as m-hydroxyphenyl cation synthons for the α-arylation of lactams.The sequence has been used to synthesize the analgesic drug meptazinol.